| Phase | Exclusion by unremitting headaches | Exclusion by failed preventives | Study duration (weeks) | Treatment arms | N | MMD change versus placebo | Number of dropouts | Dropout ratio | Reference | Acronym/NCT |
---|---|---|---|---|---|---|---|---|---|---|---|
Eptinezumab | II | - | - | 12 | placebo | 121 | Â | 0 | 0% | Dodick et al, 2019 | NCT02275117 |
100mg | 123 | -2.1 | 2 | 2% | |||||||
300mg | 120 | -2.6 | 4 | 3% | |||||||
III | + | - | 12 | placebo | 366 | Â | 2 | 1% | Lipton et al, 2020 | PROMISE-2 | |
100mg | 356 | -2.0 | 3 | 1% | |||||||
300mg | 350 | -2.6 | 8 | 2% | |||||||
Fremanezumab | II | - | ≥3 | 12 | placebo | 89 |  | 1 | 1% | Bigal et al, 2015 | NCT02021773 |
225mg (a675mg) | 88 | -1.7 | 4 | 5% | |||||||
900mg monthly | 86 | -2.0 | 3 | 3% | |||||||
III | + | ≥2 | 12 | placebo | 375 |  | 8 | 2% | Silberstein et al, 2017 | HALO | |
675mg | 376 | -1.7 | 5 | 1% | |||||||
225mg (a675mg) | 379 | -1.8 | 7 | 2% | |||||||
II/III | + | ≥2 | 12 | placebo | 191 |  | 3 | 2% | Sakai et al, 2021 | NCT03303079 | |
675mg | 191 | -1.3 | 1 | 1% | |||||||
225mg | 189 | -2.1 | 0 | 0% | |||||||
Galcanezumab | III | + | >3 | 12 | placebo | 558 | Â | 6 | 1% | Detke et al, 2018 | REGAIN |
120mg (a240mg) | 278 | -2.1 | 3 | 1% | |||||||
240mg | 277 | -1.9 | 2 | 1% | |||||||
Erenumab | II | + | >3 | 12 | placebo | 282 | Â | 2 | 1% | Tepper et al, 2017 | NCT02066415 |
70mg | 190 | -2.4 | 0 | 0% | |||||||
140mg | 188 | -2.4 | 2 | 1% |